Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030
- PMID: 28411042
- DOI: 10.1016/j.jhep.2017.03.035
Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030
Comment in
-
Reply to: "Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030".J Hepatol. 2017 Aug;67(2):420-422. doi: 10.1016/j.jhep.2017.03.033. Epub 2017 Apr 12. J Hepatol. 2017. PMID: 28412291 No abstract available.
Comment on
-
Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.J Hepatol. 2017 Jul;67(1):15-22. doi: 10.1016/j.jhep.2017.01.024. Epub 2017 Feb 9. J Hepatol. 2017. PMID: 28189752
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
